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Clinical Implications 30 
This report provides first evidence for the IL-5Rα-blocking antibody benralizumab as a 31 
treatment option for severe DRESS not responding to first-line treatment; proteomic serum 32 
analyses point towards substantial eosinophil-and T cell-related changes induced by the 33 
treatment.  34 
 35 
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Drug rash with eosinophilia and systemic symptoms (DRESS) is a rare severe 38 
hypersensitivity reaction that clinically manifests with exanthema, facial edema, enlarged 39 
lymph nodes, fever and organ damage at variable degrees (1). Eosinophil expansion in blood 40 
is a hallmark of DRESS and eosinophil tissue infiltration a main contributor to the observed 41 
organ damage and dysfunction (2). Although high-dose systemic glucocorticoids have not 42 
been evaluated in randomized clinical trials, they are currently the first-line therapy for 43 
DRESS with organ involvement. However, glucocorticoid-associated adverse events remain 44 
high and response rates are variable. Also, regardless of therapy, DRESS patients have a high, 45 
5 to 10 percent, mortality rate (2). Here, we report the first use of benralizumab (Fasenra), 46 
an interleukin (IL)-5-receptor α-chain-specific humanized monoclonal antibody (IgG1k) 47 
initially approved for eosinophilic asthma (3), in two patients with  glucocorticoid-48 
unresponsive DRESS occurring during coronavirus disease 2019 (COVID-19). The study was 49 
approved by the regional ethics review board (EK2020-01029) and conducted according to 50 
the Declaration of Helsinki. 51 
 52 
Both patients were treated in the intensive care unit for acute respiratory distress syndrome 53 
due to COVID-19. Patient 1, a 54-year-old woman, developed prominent eosinophilia 54 
followed 3 days later by cutaneous and systemic DRESS syndrome features (Table 1). 55 
Esomeprazol and piperacillin-tazobactam (details: Figure E1a), initiated almost 6 weeks prior 56 
DRESS onset and administered intermittently, were suspected as most potential culprit drugs 57 
and stopped immediately. Patient 2, a 58-year-old man with COVID-19-related multiorgan 58 
failure developed widespread maculopapular skin lesions, facial swelling, severe eosinophilia 59 
and hepatic dysfunction. The suspected potential culprit drug in his case was midazolam, 60 
which had been administered about 3 weeks before the symptoms started (Figure E1a).  In 61 
both patients, skin histopathology from cutaneous lesions on the trunk (Figure E1b) 62 










with a diagnosis of drug hypersensitivity reaction (1). DRESS diagnosis was based on the 64 
RegiSCAR criteria (scores 7 and 8, respectively; Table 1). In addition to discontinuing the 65 
potential culprit drugs, both patients received high-dose intravenous methylprednisolone 66 
(patient 1: 125mg for 3 days, 70mg for 4 days; patient 2: 125mg for 6 days), without 67 
improvement. In the setting of worsening eosinophilia (Figure 1a), deteriorating organ 68 
function, and exacerbation of their cutaneous eruption, the decision was made to initiate 69 
therapy with benralizumab (Fasenra; 30mg subcutaneously). This decision was based upon 70 
the rationale that IL-5/eosinophil axis inhibition has been reported as a successful treatment in 71 
platelet derived growth factor receptor alpha-negative hypereosinophilia (4) and that IL-5, 72 
eosinophils and the eosinophil degranulation marker eosinophilic cationic protein (ECP) were 73 
highly increased. Within two days following benralizumab administration, both patients 74 
showed a rapid and substantial drop in blood eosinophils, and, as measured in patient one, 75 
ECP (Figure 1a and Figure E2). This was paralleled clinically by an improvement of the 76 
patients’ cutaneous eruption, and a lowering of liver enzyme levels. Patient one continued to 77 
improve over the following 18 days. Patient two, however, developed disseminated 78 
intravascular coagulation secondary to COVID-19 and died from cardiac arrest after massive 79 
bleeding 17 days after the administration of Fasenra.  80 
To explore treatment-induced immunological changes, targeted serum proteomic studies were 81 
performed immediately before and one day following Fasenra administration (Online 82 
Repository Text; Figure 1b). This analysis revealed a significant reduction in levels of IL-5, 83 
IL-4, and several proteins related to cytotoxic T cell responses and activation (CD8, tumor 84 
necrosis factor, tumor necrosis factor related apoptosis inducing ligand, signaling lymphocytic 85 
activation molecule 1 and programmed cell death 1 -ligand 1), as well as the neutrophil- and 86 











Our report suggests that IL-5Rα blockade (benralizumab) is a valuable therapeutic option in 89 
critically ill patients with massive expansion of eosinophils, if eosinophils are suspected to 90 
play a pathogenic role and symptoms exacerbate despite high-dose glucocorticoids (as a first 91 
line treatment). Additional cases and studies are needed to determine the safety and efficacy 92 
of Fasenra and other monoclonal antibodies targeting the IL-5 axis (5, 6) in this setting. 93 
 94 
The context, in which our DRESS cases occurred was peculiar, i.e. developing in severely 95 
affected COVID-19 patients with acute respiratory distress syndrome. It is conceivable that 96 
the severe acute respiratory syndrome coronavirus 2 contributed directly or indirectly, via 97 
induction of a cytokine storm, to the combination of eosinophilia, critical illness and 98 
eosinophil-induced organ damage (7). Eosinopenia has been shown in COVID-19 patients 99 
with a severe disease course on the other hand, but it remains to be elucidated whether this 100 
association is pathophysiologically relevant or rather incidental (8). 101 
 102 
IL-5 is mainly produced by T helper 2 cells and is a critical mediator responsible for 103 
differentiation, activation, and, in synergy with other mediators, chemotaxis of eosinophils 104 
(9), which considerably contribute to organ damage in DRESS. Our hematologic and 105 
proteomics data suggest that Fasenra had a rapid and profound effect on eosinophils. It also 106 
points towards a benralizumab-mediated indirect regulatory effect on other cell types, 107 
possibly cytotoxic T cells. It remains to be elucidated whether a similar dynamic is observed 108 
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Figure legends  142 
 143 
Figure 1. Serological changes during benralizumab therapy. 144 
a) Line graphs showing counts (x10
9 
/ L) of the indicated leukocytes (measured daily) over 145 
the course of DRESS diagnosis and treatment in patient one and patient two, respectively. b) 146 
Heatmap showing significantly up- and down-regulated proteins (identified by Olink 147 
proteomics; p<0.05) in patient one and two prior (day 0) and after (day 1) treatment with 148 
benralizumab.  149 











Table 1. Patient details. 152 
 Patient 1 Patient 2 
General information   
Sex female male 
Age (years) 54 58 
Ethnicity Caucasian (Central Europe) Asian (China) 
Pre-existing conditions Diabetes mellitus type 2 
 
Diabetes mellitus type 2 
Multinodular goiter 
Moderate allergic asthma  
COVID-19-related information  
COVID-19 diagnosis prior 
DRESS onset (days) 
42 29 
Intubation (due to ARDS) 
prior DRESS onset (days) 
32 23 
Sars-CoV2 RT-PCR at the 
time of DRESS diagnosis  
negative negative 









Heparin-induced thrombocytopenia  
Multiple venous thrombosis 
Megacolon with focal ischemia 
Hepatopathy 
ARDS 
Hemorrhagic shock from upper 
gastronintestinal bleeding  
Acute renal insufficiency (AKI 3) 











DRESS characteristics    
RegiSCAR DRESS Score  7 8 
Detailed DRESS features (at the time of diagnosis) 
  Skin eruption 
>50% Body surface area 
Maculopapular exanthema Maculopapular exanthema 
  Fever Yes  Yes 
  Lymphadenopathy No Yes 
  Eosinophilia > 1.5 x 10
9
 / L > 1.5 x 10
9
 / L 
  Atypical lymphocytes None None 
  Organ involvement; lab values at the time of diagnosis 
  Kidney No; serum creatinin 40 µmol/l:  
eGFR 114 ml/min 
Yes; serum creatinin 142 µmol/l:  
eGFR 47 ml/min 
  Liver Yes; AST 196 U/l; ALT 263 U/l Yes; AST 106 U/l; ALT 125 U/l 
  Lung Yes; ARDS Yes; ARDS 
  Heart / Muscle Yes; myoglobin 129 µg/l Yes; myoglobin 813 µg/l 
  Pancreas No; pancreatic amylase 7 U/l No; pancreatic amylase 6 U/l, 
lipase 7 U/l 
  Other None None 
 Viral serologies at 
DRESS diagnosis (HHV6, 























(125mg 4 days, 70mg 3 days) 
Intravenous methylprednisolone 
(125mg 3 days) 
Outcome  Alive; still hospitalized 
(day 28 after DRESS diagnosis) 
Death from cardiac arrest after 
hemorrhagic shock (day 17 after 
DRESS diagnosis) 
ARDS: Acute respiratory distress syndrome; RT-PCR: real-time PCR; Sars-CoV2: severe 153 
acute respiratory syndrome coronavirus 2. Normal ranges of laboratory test values: serum 154 
creatinine: 62-106 µmol/l; creatinin kinase: <190 U/L; myoglobin: 28-72 µg/l; AST and ALT: 155 


































Online Repository: Material and Methods 
 
Ethics Approval  
The study was approved by the regional ethics review board (EK2020-01029) and conducted 
according to the Declaration of Helsinki.  
 
Sample preparation 
Blood was collected using serum tubes. Samples were processed immediately after 
collection and stored at -80 Celsius until further processing.  
 
Protein quantification in blood 
The proteomic Proseek multiplex assay by Olink (Uppsala, Sweden) is a proximity 
extension assay with oligonucleotide-labeled antibody probe pairs. It measures proteins via an 
antibody-mediated detection system linked to synthetic DNA for quantification by a real-time 
polymerase chain reaction platform. 
 
Statistical analysis of Olink data 
Olink data in Normalized protein expression (NPX) format were imported, processed 
by OlinkRPackage from Olink Proteomics (https://github.com/Olink- 
Proteomics/OlinkRPackage). The statistical comparison of protein levels between 
groups was performed with Bioconductor limma package 
(https://bioconductor.org/packages/release/bioc/html/limma.html). The fold change 










Figure Legend of Figure E1.  
a) Timelines for the respective medications of patient one and patient two. Abbreviations 
used: LTV: lopinavir; RTV: ritonavir; HCQ: hydroqychloroquine. b) Hematoxylin/eosin 
staining from lesional skin of patient two (on the trunk, framed area on the photograph). 
Histopathology showing vacuolar changes of the basal layer and a mostly perivascular, 










Figure Legend of Figure E2.  
Levels of eosinophilic cationic protein (ECP) prior (day 0) and at day two after benralizumab 
treatment in patient 1. The dashes line corresponds to the upper normal limit (l13.3 µg/L). On 
day 0, ECP levels exceeded the maximal measuring range (200 µg/L). 
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